Harrow, Inc.

Update in progress

HROW (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Harrow, Inc. is a Nashville-based eyecare pharmaceutical company that discovers, develops, and commercializes ophthalmic medicines in the United States. It operates Branded and ImprimisRx segments and offers a broad portfolio, including ImprimisRx compounded meds, ILEVO/NEVANAC, VIGAMOX, BYOOVIZ, OPUVIZ, MAXITROL, ILEVRO, FLAREX, TRIESENCE, NATACYN, TOBRADEX ST, VERKAZIA, FRESHKOTE, and more. It was formerly Harrow Health and renamed in 2023.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive